As reported in The Lancet Oncology by Marina C. Garassino, MD, and colleagues, global health status/quality of life was maintained or improved with the addition of pembrolizumab vs placebo to pemetrexed/platinum therapy for previously untreated metastatic nonsquamous non–small cell lung cancer (NSCLC).
As reported in The Lancet Oncology, Lecia V. Sequist, MD, and colleagues have found activity and an acceptable risk-benefit profile with the combination of the third-generation EGFR tyrosine kinase inhibitor osimertinib and the MET tyrosine kinase inhibitor savolitinib in patients with EGFR mutation–positive, MET-amplified non–small cell lung cancer (NSCLC) who had disease progression after treatment with EGFR tyrosine kinase inhibitors.
As reported by James L. Mulshine, MD, and colleagues in JCO Clinical Cancer Informatics, the International Association for the Study of Lung Cancer (IASLC) is developing the Early Lung Imaging Confederation “to serve as an open-source, international, universally accessible environment to analyze large collections of quality-controlled low-dose computed tomography (CT) images and associated biomedical data for research and routine screening care.”
A multicenter retrospective study investigating the incidence of pneumonitis and the incidence, risk factors, and clinical characteristics of radiation recall pneumonitis in patients with non–small cell lung cancer (NSCLC) who had received nivolumab found the incidence of radiation recall pneumonitis was 5.4% among patients with a previous history of thoracic radiation therapy, although there were no significant risk factors of radiation recall pneumonitis. The study by Shimokawaji et al was presented at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium.